NCT03407651 - Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

March 15, 2019

Study Completion Date

April 13, 2019

Conditions

Hemophilia A With InhibitorHemophilia B With Inhibitor

Interventions

BIOLOGICAL

Coagulation Factor VIIa variant

Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.

Trial Locations (9)

Unknown

Hematology Center after Prof. R. Yeolyan, Yerevan

"JSC K.Eristavi National Center of Experimental and Clinical Surgery", Tbilisi

LTD M.Zodelava Hematology Centre, Tbilisi

LTD Medinvest - Institute of Hematology and Transfusiology, Tbilisi

Gabinet Lekarski, Bartosz Korczowski, Rzeszów

Regional Clinical Hospital, Kemerovo

FGU Kirov Scientific Research, Kirov

Center for Hemophilia Treatment, Saint Petersburg

Haemophilia Comprehensive Care Centre, Johannesburg